MYDA Advisors LLC grew its holdings in BrainsWay Ltd. (NASDAQ:BWAY - Free Report) by 100.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 120,100 shares of the company's stock after acquiring an additional 60,100 shares during the period. MYDA Advisors LLC owned 0.64% of BrainsWay worth $1,133,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Phoenix Financial Ltd. grew its holdings in BrainsWay by 100.8% during the fourth quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company's stock valued at $4,552,000 after purchasing an additional 242,366 shares during the period. ARK Investment Management LLC purchased a new stake in BrainsWay in the 4th quarter worth approximately $1,656,000. Zuckerman Investment Group LLC raised its stake in BrainsWay by 346.4% during the 4th quarter. Zuckerman Investment Group LLC now owns 67,000 shares of the company's stock worth $667,000 after acquiring an additional 51,991 shares during the period. JPMorgan Chase & Co. boosted its position in shares of BrainsWay by 61.9% in the fourth quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company's stock worth $226,000 after purchasing an additional 9,149 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock worth $207,000 after purchasing an additional 2,144 shares in the last quarter. Hedge funds and other institutional investors own 30.11% of the company's stock.
BrainsWay Stock Down 1.3 %
BWAY stock traded down $0.12 during mid-day trading on Friday, hitting $9.01. The company had a trading volume of 12,452 shares, compared to its average volume of 72,432. BrainsWay Ltd. has a 12-month low of $4.72 and a 12-month high of $11.79. The company has a 50-day moving average price of $9.40 and a 200 day moving average price of $9.77. The company has a market capitalization of $169.92 million, a price-to-earnings ratio of 90.06 and a beta of 1.17.
Analyst Ratings Changes
Separately, HC Wainwright restated a "buy" rating and issued a $16.00 price objective on shares of BrainsWay in a research report on Wednesday, March 12th.
Read Our Latest Stock Analysis on BrainsWay
BrainsWay Profile
(
Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Recommended Stories
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
